Home >> News >> Business >> Asthma And COPD Drugs Market Is Expected To Reach US$ 56.5 Bn By 2025

Asthma And COPD Drugs Market Is Expected To Reach US$ 56.5 Bn By 2025

Product Summary

The study is given to the analysis of the latest growth trends and prospects for the Asthma And COPD Drugs market.

The section “Asthma And COPD Drugs Market” includes an examination of the situation in major sections of the Asthma And COPD Drugs market. The markets in European Union countries are examined in more detail, giving a timeline of financial results reported by major 3PL providers in 2017.

Browse full report: https://www.credenceresearch.com/report/asthma-and-copd-drugs-market

Market Insight:

Globally, asthma and COPD is one the leading chronic respiratory diseases, with high prevalence and increasing health care and economic burden. Thus, disease represent a lucrative market for pharmaceutical companies. COPD is rated to be the fourth most common cause of mortality, and expected to reach third position by 2030, in case the risk such as smoking, pollution is not addressed. Gradually over the period of time the treatment of asthma and COPD shows improvement, with novel drugs and treatment strategies, along with usage of non-pharmacologic treatment. It has being observed there is being surge in prevalence of asthma and COPD in developed and developing countries. In developed countries, there is being rise in prevalence of asthma due to lifestyle changes in terms of food habit, low level of exercise, etc., while in developing countries the prevalence is due to pollution and smoking.

The global asthma and COPD drugs market is segmented by drug type into anti-inflammatory drugs, bronchodilator monotherapy and combination drugs. Anti-inflammatory drugs includes corticosteroids, anti-leukotrienes and monoclonal antibodies. Bronchodilator monotherapy includes short-acting beta2-agonist (SABAs) and long-acting beta2-agonist (LABAs) and anticholinergic drugs. Amongst all, combination therapy of long-acting beta2 agonist (LABA)/ inhaled corticosteroid (ICS) dominates the market. The combination therapy that include Symbicort (AstraZeneca), Advair (GlaxoSmithKline) is most preferred treatment against asthma/ COPD, due to better efficacy and less side effects.

As of the current market scenario, North America together dominate the global asthma and COPD drugs market followed by the European market. Rising prevalence of asthma and COPD due to pollution, change in lifestyle, entry of generics and novel therapies in the market. Asia Pacific is anticipated to be the fastest growing market for the forecast period. Emerging economies such India, China due to industrialization, demographic changes, urbanization there is been rise in pollution thus increase in prevalence of asthma and COPD population.

Market Competition Assessment:

Key players in the global asthma and COPD drugs market are Novartis AG, Merck & Co, GlaxoSmithKline Plc, Boehringer Ingelheim Gmbh, Nycomed, Abbott Laboratories, AstraZeneca, Roche Holding AG, Teva Pharmaceutical Industries, Vectura Group, Pfizer Inc. and others.

“Asthma And COPD Drugs Market” is a new report by us that explains how companies’ acquisition expenditures, media spend, business strategies, marketing and sales strategies and practices, and business plan are set to change in 2017-2018. This paper gives you access to the category-level spending forecasts, business challenges, budgets, supplier selection criteria, the current size of the marketing and promotion budgets and investment opportunities for senior-level officials. The report also identifies the expected growth of buyers and suppliers, capital expenditure, staff hiring, M and A, and e-procurement. This report not only gives access to the views and strategies of business decision makers and rivals but also examines their actions circling business priorities. The report also provides access to information categorized by company type and sizes, region,

Introduction and Landscape

Why was the report written?

This report is the result of an extensive survey drawn from Our Research’s elite panel of leading global senior level executives from enterprises such as such as medical devices, mining, packaging, power, oil, and gas, food and beverage, airports and pharmaceutical. The report covers key topics such as appropriation behaviors and strategies, the current size of the marketing and advertising budgets. Besides the report also recognizes the threats and possibilities, economic outlook trends, media channel spending outlooks, M and A expectations, marketing agency selection models, media budgets, business challenges and confidence among senior-level executives across various industries. Most secondary research papers are based on general industry drivers and do not understand the industry officials’ attitude and changing behaviors, creating a gap in showing the business opportunity of the industry. In an effort to bridge this gap, Our Research created this primary-research based report by selecting the opinions of various stakeholders in the value-chain of the industry

This report offers:

  • Analysis of several products, and regions that would provide the clear understanding of the ongoing and future trends in the global Asthma And COPD Drugs market
  • Assessment of market dynamics such as drivers, restraints, and opportunities prevalent in the market
  • Quantitative assessment of the current market size and future estimations for the period from 2016 to 2026, along with CAGRs for the period from 2018 to 2026
  • Company profiles that will highlight key information about the imperative players operating in the global Asthma And COPD Drugs devices market

Here you can get an updated sample on this report: https://www.credenceresearch.com/sample-request/58486

About us:

Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non-legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we’ve manufactured a firm extraordinarily prepared to this task.

Who we are

Credence Research is a worldwide firm, containing more than 15 research consultants and almost 100 research and information professionals.

Our customers mirror our worldwide nature. Around 45% are in Europe, 30% in the Americas, 13% in the Asia Pacific and 12% in the Middle East and Africa.

Our firm is intended to work as one. We are a solitary global research organization united by a solid arrangement of qualities, concentrated on customer effect.

Contact Us:

Credence Research Inc.

105 N 1st ST #429

SAN JOSE

CA 95103

United States

Email:

sales@credenceresearch.com

http://www.credenceresearch.com

Leave a Reply

Your email address will not be published. Required fields are marked *